Development of nevirapine resistance in children exposed to the prevention of mother-to-child HIV-1 transmission programme in Maputo, Mozambique

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Antunes, Francisco ^a   Zindoga, Pereira ^b   Gomes, Perpétua ^c   Augusto, Orvalho ^d   Mahumane, Isabel ^b   Veloso, Luís ^c   Valadas, Emília ^a   Camacho, Ricardo ^e  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^c Laboratório de Microbiologia Clínica E Biologia Molecular Serviço de Patologia Clínica Centro Hospitalar Lisboa Ocidental ^*  (Portugal)

^d EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DISEASE TRANSMISSION; FEMALE; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MOZAMBIQUE; NEWBORN; PLACENTAL TRANSFER; PREVALENCE; PREVENTION OF MOTHER TO CHILD TRANSMISSION; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; ANTIVIRAL RESISTANCE; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; HIV INFECTIONS; INFECTION CONTROL; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION; VIRUS GENE;

ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTION CONTROL; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOZAMBIQUE; NEVIRAPINE;

EID: 84941361103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131994     Document Type: Article

References (40)

1. UNAIDS. World AIDS Day Report-2011. Available: http://www.unaids.org/en/resources/publications/2011.
2. UNAIDS. Outlook Report: 30 years into the AIDS epidemic. 2011. Available: http://www.unaids.org/en/resources/publications/2011.
3. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004; 351:229-40. PMID: 15247339.
4. UNAIDS. UNAIDS Report On The Global AIDS Epidemic 2013. 2013. Available: http://www.unaids.org/en/resources/documents/2013/20130923-UNAIDS-Global-R-eport-2013.
5. UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive 2011-2015. 2011. Available: http://www.unaids.org/en/resources/documents/2011.
6. Whitson D, Horth R and Gonçalves S. Analysis of HIV prevention response and modes of HIV transmission: The UNAIDS-Gamet Supported Synthesis Process. 2008: 11-2. Available: http://www.unaidsrstesa.org/resources/reports/analysis-hiv-prevention-response-and-modes-hiv-transmissionunaids-gamet-supported.
7. MISAU. Boletim epidemiológico do Ministério da Saúde de Moçambique MISAU-Resultados da ronda serologica. 2009. Available: http://www.misau.gov.mz/index.php/boletins-epidemiologicos.
8. Guay LA, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354:795-802. PMID: 10485720.
9. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003; 187:725-35. PMID: 12599045.
10. Lallemant M, Jourdain G, Le-Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, Chaix ML, Thiebaut R, Masquelier B, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004; 351:217-28. PMID: 15247338.
11. Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: A meta-analysis. Int J Epidemiol. 2007; 36:1009-21. PMID: 17533166.
12. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356:135-47. PMID: 17215531.
13. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. The N Engl Med. 2010; 363:1510-1520.
14. WHO. Rapid Advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infant-version 2. 2010.
15. Bila DC, Young P, Merks H, Vubil AS, Mahomed M, Augusto A, et al. Evolution of primary HIV drug resistance in a subtype C dominated epidemic in Mozambique. PLoS One. 2013; 8:e68213. doi:10.1371/journal.pone.0068213 PMID: 23935858.
16. Cunningham S, Ank B, Lewis D, Lu W, Wantman M, Dileanis JA, et al. Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequencebased analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol. 2001; 39:1254-7. PMID: 11283037.
17. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003; 31: 298-303. PMID: 12520007.
18. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005; 21: 3797-3800. PMID: 16076886.
19. Kamoto K and Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther. 2008; 13 Suppl 2:83-7. PMID: 18575195.
20. Frank M, von Kleist M, Kunz A, Harms G, Schutte C and Kloft C. Quantifying the impact of nevirapinebased prophylaxis strategies to prevent mother-to-child transmission of HIV-1: A combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. Antimicrob Agents Chemother. 2011; 55:5529-40. doi:10.1128/AAC.00741-11 PMID: 21947390.
21. Fogel J, Hoover DR, Sun J, Mofenson LM, Fowler MG, Taylor AW, et al. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS. 2011; 25:911-7. doi:10.1097/QAD.0b013e328344fedc PMID: 21487249.
22. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011; 25:1461-9. doi:10.1097/QAD.0b013e3283492180 PMID: 21633285.
23. Micek MA, Blanco AJ, Beck IA, Dross S, Matunha L, Montoya P, et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis. 2010; 50:1405-14. doi: 10.1086/652151 PMID: 20384494.
24. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al. Resistance after singledose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS. 2005; 19:2167-9. PMID: 16284468.
25. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005; 192:30-6. PMID: 15942891.
26. Vaz P, Augusto O, Bila D, Macassa E, Vubil A, Jani IV, et al. Surveillance of HIV drug resistance in children receiving antiretroviral therapy: A pilot study of the World Health Organization's generic protocol in Maputo, Mozambique. Clin Infect Dis. 2012; 54 Suppl 4:S369-74. doi:10.1093/cid/cis006 PMID: 22544205.
27. McMahon DK, Zheng L, Hitti J, Chan ES, Halvas EK, Hong F, et al. Greater suppression of nevirapine resistance with 21-vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clin Infect Dis. 2013; 56:1044-51. doi:10.1093/cid/cis1219PMID: 23300238.
28. Adjé-Touré C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses. 2008; 24:911-7. doi:10.1089/aid.2007.0264 PMID: 18593341.
29. Gantt S, Payant R, Carlsson J, Micek MA, Blanco AJ, Beck IA, et al. Nevirapine-resistant HIV-1 DNA in breast milk after single-dose nevirapine with or without zidovudine for prevention of mother-to-child transmission. J Pediatric Infect Dis Soc. 2012; 1:244-9. PMID: 23687579.
30. Micek MA, Dross S, Blanco AJ, Beck IA, Matunha L, Seidel K, et al. Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique. J Infect Dis. 2014; 4:641-5.
31. Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, et al. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc. 2011; 14:30. doi:10.1186/1758-2652-14-30 PMID: 21663632.
32. Shao ER, Kifaro EG, Chilumba IB, Nyombi BM, Moyo S, Gaseitsiwe S, et al. HIV-1 drug mutations in children from northern Tanzania. J Antimicrob Chemother. 2014; 7:1928-32.
33. Vaz P, Chaix ML, Jani I, Macassa E, Bila D, Vubil A, et al. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J. 2009; 28:e283-7. doi:10.1097/INF.0b013e3181ba6c92 PMID: 19907359.
34. Maiga AI, Fofana DB, Maiga AC, Diallo F, Ait-Arkoub Z, Daou F, et al. Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Segou and Bamako, Mali. AIDS Res Hum Retroviruses. 2013; 29:182-6. doi:10.1089/AID.2012.0118 PMID: 22823755.
35. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001; 15:1951-7. PMID: 11600822.
36. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005; 192:24-9. PMID: 15942890.
37. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007; 44:148-53. PMID: 17117145.
38. Church JD, Omer SB, Guay LA, Huang W, Lidstrom J, Musoke P, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis. 2008; 198:1075-82. doi:10.1086/591503 PMID: 18684096.
39. Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, et al. Nevirapine resistance and breast-milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PloS one. 2009; 4:e4096. doi:10.1371/journal.pone.0004096 PMID: 19119321.
40. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, Frenkel L, Britto P, Roongpisuthipong A, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. Clin Infect Dis. 2012; 54:285-93. doi:10.1093/cid/cir798 PMID: 22144539.